{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:28:07Z","timestamp":1793993287379,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Worsening of the overdose crisis in the USA has been linked to the continuing proliferation of non-pharmaceutical fentanyl (NPF). The recent wave of NPF spread in the USA has been fueled by an increased presence of counterfeit pills that contain NPF. This qualitative study aims to characterize the motivation and practices of counterfeit NPF pill initiation and use among individuals using illicit opioids in Arizona.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between October 2020 and May 2021, semi-structured interviews were conducted with 22 individuals meeting the following eligibility criteria: (1) 18\u00a0years or older; (2) residence in Arizona; and (3) use of illicit opioids in the past 30\u00a0days and\/or opioid use disorder treatment in the past 12\u00a0months. Participants were recruited through referrals by a harm reduction organization, craigslist ads, and referrals by other participants. Interviews were conducted virtually via Zoom. Qualitative interviews were transcribed and analyzed thematically using NVivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 22 participants, 64% were male, and 45% were ethnic minorities. Age ranged between 25 and 51\u00a0years old. Participants noted significant recent increases in the availability of counterfeit NPF pills (\u201cblues,\u201d \u201cdirty oxys\u201d) that were most commonly used by smoking. The majority indicated first trying NPF pills in the past year, and the first use often occurred in situations of reduced access to heroin or pharmaceutical opioids. Participant decisions to switch over to more frequent NPF pill use or to maintain some levels of heroin use were shaped by local drug availability trends and personal experiences with NPF effects. They were also influenced by conflicting views of social acceptability of pharmaceutical-like drugs, perceived harms of NPF in terms of overdose risks and increased difficulty of quitting, and perceived benefits of switching to the non-injection route of opioid administration (e.g., from injecting heroin to smoking NPF pills).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings highlight the need for the implementation of novel policy, treatment, and harm reduction approaches to address the growing unpredictability of drug supply and NPF pill-specific risks, attitudes, and behaviors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00634-4","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T11:03:04Z","timestamp":1653476584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["\u201cThey say it\u2019s fentanyl, but they honestly look like Perc 30s\u201d: Initiation and use of counterfeit fentanyl pills"],"prefix":"10.1186","volume":"19","author":[{"given":"Raminta","family":"Daniulaityte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylin","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seol","family":"Ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley N.","family":"Doebbeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"634_CR1","unstructured":"Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2021."},{"issue":"4","key":"634_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"key":"634_CR3","first-page":"2020","volume":"17","author":"Health Alert Network","year":"2020","unstructured":"Health Alert Network. Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. CDC. 2020;17:2020.","journal-title":"CDC"},{"issue":"6","key":"634_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","volume":"70","author":"CL Mattson","year":"2021","unstructured":"Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"634_CR5","first-page":"1","volume":"426","author":"H Hedegaard","year":"2021","unstructured":"Hedegaard H, Minino AM, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999\u20132020. NCHS Data Brief. 2021;426:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"634_CR6","doi-asserted-by":"publisher","first-page":"108314","DOI":"10.1016\/j.drugalcdep.2020.108314","volume":"216","author":"CL Shover","year":"2020","unstructured":"Shover CL, Falasinnu TO, Dwyer CL, Santos NB, Cunningham NJ, Freedman RB, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance. Drug Alcohol Depend. 2020;216:108314.","journal-title":"Drug Alcohol Depend"},{"key":"634_CR7","unstructured":"Mully A, Courter S, Vidale T. 2020 EDGE Report, Enhanced Drug and Gang Enforcement Startegy, AZ. Phoenix, AZ: Arizona Criminal Justice Commission (ACJC) developed and implemented a 2020."},{"key":"634_CR8","unstructured":"DEA. 2020 National Drug Threat Assessment U.S. Department of Justice, Drug Enforcement Adminstration (DEA); 2021 March 2021."},{"issue":"50","key":"634_CR9","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","volume":"70","author":"J O'Donnell","year":"2021","unstructured":"O\u2019Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and characteristics of drug overdose deaths involving illicitly manufactured Fentanyls\u2014United States, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70(50):1740\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"634_CR10","unstructured":"LAPPA. Pill Press Laws: A Forgotten aspect of counterfeit drug-making. Legislative analysis and public policy association; 2021 March 2021."},{"key":"634_CR11","unstructured":"PSM. All 50 states reported deadly counterfeit pills made with fentanyl. The Partnership for Safemedicines.org; 2020 October 2020."},{"key":"634_CR12","doi-asserted-by":"publisher","DOI":"10.7249\/RR3117","volume-title":"The future of fentanyl and other synthetic opioids","author":"B Pardo","year":"2019","unstructured":"Pardo B, Taylor J, Caulkins JP, Kilmer B, Reuter P, Stein BD. The future of fentanyl and other synthetic opioids. Santa Monica: RAND Corporation; 2019."},{"issue":"2","key":"634_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","volume":"50","author":"SG Mars","year":"2018","unstructured":"Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore. MD J Psychoact Drugs. 2018;50(2):167\u201376.","journal-title":"MD J Psychoact Drugs"},{"key":"634_CR14","doi-asserted-by":"publisher","first-page":"103463","DOI":"10.1016\/j.drugpo.2021.103463","volume":"99","author":"R Daniulaityte","year":"2022","unstructured":"Daniulaityte R, Silverstein SM, Getz K, Juhascik M, McElhinny M, Dudley S. Lay knowledge and practices of methamphetamine use to manage opioid-related overdose risks. Int J Drug Policy. 2022;99:103463.","journal-title":"Int J Drug Policy"},{"key":"634_CR15","unstructured":"Arizona Substance Abuse Partnership. Counterfeit Fentanyl: Arizona Data Trends, Interdiction, and Statewide Prevention. Governor\u2019s Office of Youth, Faith, and Family; Arizona Substance Abuse Partnership; 2020 December 2020."},{"key":"634_CR16","unstructured":"Daniulaityte R, Ruhter L, Katz C. Drug Overdose Deaths in Arizona During the Early Stages of the COVID-19 Pandemic. AZ-SUDORS Report. Phoenix, AZ: Center for Violence Prevention and Community Safety; College of Health Solutions, Arizona State University; 2021."},{"key":"634_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107\u201311.","journal-title":"Int J Drug Policy"},{"key":"634_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: exploring users\u2019 perceptions of fentanyl-adulterated and -substituted \u2018heroin.\u2019 Int J Drug Policy. 2017;46:146\u201355.","journal-title":"Int J Drug Policy"},{"key":"634_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0213-2","author":"MS Krieger","year":"2018","unstructured":"Krieger MS, Goedel WC, Buxton JA, Lysyshyn M, Bernstein E, Sherman SG, et al. Use of rapid fentanyl test strips among young adults who use drugs. Int J Drug Policy. 2018. https:\/\/doi.org\/10.1186\/s12954-018-0213-2.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"634_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12954-018-0240-z","volume":"15","author":"JN Park","year":"2018","unstructured":"Park JN, Weir BW, Allen ST, Chaulk P, Sherman SG. Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD. Harm Reduct J. 2018;15(1):34.","journal-title":"Harm Reduct J"},{"key":"634_CR21","doi-asserted-by":"publisher","first-page":"107547","DOI":"10.1016\/j.drugalcdep.2019.107547","volume":"204","author":"KB Morales","year":"2019","unstructured":"Morales KB, Park JN, Glick JL, Rouhani S, Green TC, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend. 2019;204:107547.","journal-title":"Drug Alcohol Depend"},{"key":"634_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","volume":"46","author":"JJ Carroll","year":"2017","unstructured":"Carroll JJ, Marshall BDL, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. Int J Drug Policy. 2017;46:136\u201345.","journal-title":"Int J Drug Policy"},{"key":"634_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addbeh.2017.01.014","volume":"68","author":"A Macmadu","year":"2017","unstructured":"Macmadu A, Carroll JJ, Hadland SE, Green TC, Marshall BD. Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically. Addict Behav. 2017;68:35\u20138.","journal-title":"Addict Behav"},{"key":"634_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.drugpo.2019.05.020","volume":"71","author":"R Daniulaityte","year":"2019","unstructured":"Daniulaityte R, Carlson RG, Juhascik MP, Strayer KE, Sizemore IE. Street fentanyl use: experiences, preferences, and concordance between self-reports and urine toxicology. Int J Drug Policy. 2019;71:3\u20139.","journal-title":"Int J Drug Policy"},{"key":"634_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. \u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76\u201383.","journal-title":"Int J Drug Policy"},{"key":"634_CR26","unstructured":"QSR International. NVivo. Released in March 2020 ed: QSR International Pty Ltd.; 2020."},{"key":"634_CR27","first-page":"451","volume-title":"Analyzing qualitative data: systematic approaches","author":"HR Bernard","year":"2010","unstructured":"Bernard HR, Ryan GW. Analyzing qualitative data: systematic approaches. Thousand Oaks: Sage; 2010. p. 451."},{"issue":"6","key":"634_CR28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/add.13314","volume":"111","author":"J Neale","year":"2016","unstructured":"Neale J. Iterative categorization (IC): a systematic technique for analysing qualitative data. Addiction. 2016;111(6):1096\u2013106.","journal-title":"Addiction"},{"key":"634_CR29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u20138.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"634_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.drugpo.2012.01.012","volume":"23","author":"R Daniulaityte","year":"2012","unstructured":"Daniulaityte R, Falck R, Carlson RG. \u201cI\u2019m not afraid of those ones just 'cause they\u2019ve been prescribed\u201d: perceptions of risk among illicit users of pharmaceutical opioids. Int J Drug Policy. 2012;23(5):374\u201384.","journal-title":"Int J Drug Policy"},{"key":"634_CR31","doi-asserted-by":"publisher","first-page":"109003","DOI":"10.1016\/j.drugalcdep.2021.109003","volume":"227","author":"AH Kral","year":"2021","unstructured":"Kral AH, Lambdin BH, Browne EN, Wenger LD, Bluthenthal RN, Zibbell JE, et al. Transition from injecting opioids to smoking fentanyl in San Francisco. California Drug Alcohol Depend. 2021;227:109003.","journal-title":"California Drug Alcohol Depend"},{"issue":"2","key":"634_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.drugpo.2010.01.011","volume":"21","author":"J Bridge","year":"2010","unstructured":"Bridge J. Route transition interventions: potential public health gains from reducing or preventing injecting. Int J Drug Policy. 2010;21(2):125\u20138.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"634_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/09595239800187001","volume":"17","author":"J Strang","year":"1998","unstructured":"Strang J, Bearn J, Farrell M, Finch E, Gossop M, Griffiths P, et al. Route of drug use and its implications for drug effect, risk of dependence and health consequences. Drug Alcohol Rev. 1998;17(2):197\u2013211.","journal-title":"Drug Alcohol Rev"},{"issue":"11","key":"634_CR34","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/j.1360-0443.1992.tb02660.x","volume":"87","author":"M Gossop","year":"1992","unstructured":"Gossop M, Griffiths P, Powis B, Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict. 1992;87(11):1527\u201336.","journal-title":"Br J Addict"},{"issue":"9","key":"634_CR35","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1007\/s10461-019-02467-y","volume":"23","author":"D Des Jarlais","year":"2019","unstructured":"Des Jarlais D, Uuskula A, Talu A, Barnes DM, Raag M, Arasteh K, et al. Implementing an updated \u201cbreak the cycle\u201d intervention to reduce initiating persons into injecting drug use in an eastern European and a us \u201copioid epidemic\u201d setting. AIDS Behav. 2019;23(9):2304\u201314.","journal-title":"AIDS Behav"},{"key":"634_CR36","unstructured":"Daniulaityte R, Ruhter L, Katz CM. Characteristics of Non-pharmaceutical Fentanyl-related Overdose Deaths in Arizona, July 2019\u2013June 2020. AZ-SUDORS Report. Phoenix, AZ: Center for Violence Prevention & Community Safety, Arizona State University; 2021."},{"key":"634_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.drugpo.2018.04.017","volume":"58","author":"CR McGowan","year":"2018","unstructured":"McGowan CR, Harris M, Platt L, Hope V, Rhodes T. Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: do we know enough to promote it? Int J Drug Policy. 2018;58:31\u20136.","journal-title":"Int J Drug Policy"},{"key":"634_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122\u20138.","journal-title":"Int J Drug Policy"},{"key":"634_CR39","doi-asserted-by":"publisher","first-page":"103147","DOI":"10.1016\/j.drugpo.2021.103147","volume":"92","author":"MK Reed","year":"2021","unstructured":"Reed MK, Roth AM, Tabb LP, Groves AK, Lankenau SE. \u201cI probably got a minute\u201d: perceptions of fentanyl test strip use among people who use stimulants. Int J Drug Policy. 2021;92:103147.","journal-title":"Int J Drug Policy"},{"key":"634_CR40","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.06.020","volume":"190","author":"KW Tupper","year":"2018","unstructured":"Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"634_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-020-00373-4","volume":"17","author":"B Wallace","year":"2020","unstructured":"Wallace B, van Roode T, Pagan F, Phillips P, Wagner H, Calder S, et al. What is needed for implementing drug checking services in the context of the overdose crisis. A qualitative study to explore perspectives of potential service users. Harm Reduct J. 2020;17(1):29.","journal-title":"Harm Reduct J"},{"issue":"1","key":"634_CR42","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jrh.12328","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113\u201321.","journal-title":"J Rural Health"},{"issue":"2","key":"634_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/wps.20846","volume":"20","author":"ND Volkow","year":"2021","unstructured":"Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry. 2021;20(2):195\u20136.","journal-title":"World Psychiatry"},{"issue":"1","key":"634_CR44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13722-021-00244-8","volume":"16","author":"KK Adams","year":"2021","unstructured":"Adams KK, Machnicz M, Sobieraj DM. Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. Addict Sci Clin Pract. 2021;16(1):36.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"634_CR45","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1503\/cmaj.74018","volume":"192","author":"PA Randhawa","year":"2020","unstructured":"Randhawa PA, Brar R, Nolan S. Buprenorphine-naloxone, \u201cmicrodosing\u201d: an alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market. CMAJ. 2020;192(3):E73.","journal-title":"CMAJ"},{"key":"634_CR46","doi-asserted-by":"publisher","first-page":"108678","DOI":"10.1016\/j.drugalcdep.2021.108678","volume":"222","author":"ND Volkow","year":"2021","unstructured":"Volkow ND. To end the opioid crisis, we must address painful social disparities. Drug Alcohol Depend. 2021;222:108678.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"634_CR47","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/dar.13058","volume":"39","author":"D Stevens-Watkins","year":"2020","unstructured":"Stevens-Watkins D. Opioid-related overdose deaths among African Americans: implications for research, practice and policy. Drug Alcohol Rev. 2020;39(7):857\u201361.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"634_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/dar.13335","volume":"41","author":"E Scallan","year":"2022","unstructured":"Scallan E, Bodkin C, Wiwcharuk J, O\u2019Shea T, Lennox R. Finding stability amidst the COVID-19 pandemic: the impact of emergency temporary housing for people who use drugs. Drug Alcohol Rev. 2022;41(1):7\u20138.","journal-title":"Drug Alcohol Rev"},{"issue":"1_suppl","key":"634_CR49","doi-asserted-by":"publisher","first-page":"18S","DOI":"10.1177\/00333549211015662","volume":"136","author":"P Canning","year":"2021","unstructured":"Canning P, Doyon S, Ali S, Logan SB, Alter A, Hart K, et al. Using surveillance with near-real-time alerts during a cluster of overdoses from fentanyl-contaminated crack cocaine Connecticut June 2019. Public Health Rep. 2021;136(1_suppl):18S-23S.","journal-title":"Public Health Rep"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00634-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T23:03:15Z","timestamp":1653519795000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00634-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00634-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"12 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Arizona State University Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}